2,4-dihydroxy-3-dipropyl-1',1',1'-trifluoroacetophenone oxime | 724471-16-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-dihydroxy-3-dipropyl-1',1',1'-trifluoroacetophenone oxime
• 英文别名: 1-(2,4-Dihydroxy-3-propylphenyl)-2,2,2-trifluoroethanone oxime；4-[N-hydroxy-C-(trifluoromethyl)carbonimidoyl]-2-propylbenzene-1,3-diol
• CAS: 724471-16-3
• 化学式: C₁₁H₁₂F₃NO₃
• 分子量: 263.216
• InChiKey: OPCKGPTXKUOJJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  73
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2,4-dihydroxy-3-dipropyl-1',1',1'-trifluoroacetophenone oxime 在 吡啶 、 三乙胺 作用下， 反应 3.0h， 生成 7-丙基-3-(三氟甲基)苯并[d]异恶唑-6-醇
  参考文献：
  名称：

  Discovery of a Novel Series of Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists for the Treatment of Type 2 Diabetes and Dyslipidemia

  摘要：

  A series of 2-aryloxy-2-methyl-propionic acid compounds and related analogues were designed, synthesized, and evaluated for their PPAR agonist activities. 2-[(5,7-Dipropyl-3-trifluoromethyl)-benzisoxazol-6-yloxy]-2-methylpropionic acid (4) was identified as a PPAR alpha/gamma dual agonist with relative PPAR alpha selectivity and demonstrated potent efficacy in lowering both glucose and lipids in animal models without causing body weight gain. The PPAR alpha activity of 4 appeared to have played a significant role in lowering glucose levels in db/db mice.

  DOI：

  10.1021/jm048993p
• 作为产物：
  描述：

  2-正丙基间苯二酚 在 三氯化铝 、 盐酸羟胺 、 sodium acetate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 2,4-dihydroxy-3-dipropyl-1',1',1'-trifluoroacetophenone oxime
  参考文献：
  名称：

  Discovery of a Novel Series of Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists for the Treatment of Type 2 Diabetes and Dyslipidemia

  摘要：

  A series of 2-aryloxy-2-methyl-propionic acid compounds and related analogues were designed, synthesized, and evaluated for their PPAR agonist activities. 2-[(5,7-Dipropyl-3-trifluoromethyl)-benzisoxazol-6-yloxy]-2-methylpropionic acid (4) was identified as a PPAR alpha/gamma dual agonist with relative PPAR alpha selectivity and demonstrated potent efficacy in lowering both glucose and lipids in animal models without causing body weight gain. The PPAR alpha activity of 4 appeared to have played a significant role in lowering glucose levels in db/db mice.

  DOI：

  10.1021/jm048993p

文献信息

• Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
  申请人：Cantin Louis-David

  公开号：US20060084680A1

  公开（公告）日：2006-04-20

  This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.

  本发明涉及一种新型的茚三酸衍生物，其可用于治疗糖尿病、肥胖症、高脂血症和动脉粥样硬化等疾病。本发明还涉及用于制备茚三酸衍生物的中间体以及制备方法。
• Indole acetic acid derivatives and their use as pharmaceutical agents
  申请人：Ma Xin

  公开号：US20060264486A1

  公开（公告）日：2006-11-23

  This invention is directed to indole acetic acid derivatives and their use in pharmaceutical compositions for the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic disease. The invention is also directed to intermediates useful in preparation of indole acetic derivatives and to methods of preparation.

  这项发明涉及吲哚乙酸衍生物及其在制备药物组合物中的应用，用于治疗糖尿病、肥胖症、高脂血症和动脉粥样硬化等疾病。该发明还涉及在制备吲哚乙酸衍生物中有用的中间体和制备方法。
• WO2007/81335
  申请人：——

  公开号：——

  公开（公告）日：——
• O-Arylmandelic acids as highly selective human PPAR α/γ agonists
  作者：Alan D Adams、Zao Hu、Derek von Langen、Adonis Dadiz、Alex Elbrecht、Karen L MacNaul、Joel P Berger、Gaochao Zhou、Thomas W Doebber、Roger Meurer、Michael J Forrest、David E Moller、A Brian Jones

  DOI：10.1016/s0960-894x(03)00702-9

  日期：2003.10

  A new class of O-arylmandelic acid PPAR agonists show excellent anti-hyperglycemic efficacy in a db/db mouse model of DM2. These PPARalpha-weighted agonists do not show the typical PPARgamma associated side effects of BAT proliferation and cardiac hypertrophy in a rat tolerability assay. (C) 2003 Elsevier Ltd. All rights reserved.